Outcomes following cardiac resynchronisation therapy in older people
Nawaz Z Safdar1, Stephe Kamalathasan2, Ankit Gupta1
1School of Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, UK.
Insights
Older patients benefit from cardiac resynchronisation therapy (CRT) for heart failure management, showing similar symptomatic and functional improvements. Despite higher comorbidities, CRT is effective in the aging population, though long-term survival varies by age.
Area of Science:
- Cardiology
- Geriatric Medicine
- Medical Devices
Background:
- Older patients with heart failure are often undertreated with cardiac resynchronisation therapy (CRT).
- Differences in clinical response, complications, and outcomes between older and younger patients receiving CRT are not well-defined.
Purpose of the Study:
- To compare the clinical response, complications, and outcomes of cardiac resynchronisation therapy (CRT) in older versus younger patients with heart failure.
- To evaluate the efficacy and safety of CRT in an aging population.
Main Methods:
- Retrospective cohort study of 574 patients implanted with CRT devices between March 2008 and July 2017.
- Patients were stratified into three age groups: <70, 70-79, and ≥80 years.
- Data collected included complications, symptomatic and echocardiographic response, heart failure hospitalisation, and all-cause mortality.
Main Results:
- Older patients (≥80 years) presented with worse symptoms and more comorbidities but had similar left ventricular function at baseline.
- Complications were infrequent and not more common in older patients.
- Age did not predict symptomatic or echocardiographic response to CRT; however, 10-year survival was significantly lower in older age groups.
Conclusions:
- Cardiac resynchronisation therapy (CRT) provides similar benefits in symptoms and left ventricular function for older patients compared to younger patients.
- Despite a higher comorbidity burden and less optimal medical therapy, CRT is effective in the aging heart failure population.
- These findings support the expanded use of CRT in older adults.
Introduction:
Older patients may be less likely to receive cardiac resynchronisation therapy (CRT) for the management of heart failure. We aimed to describe the differences in clinical response, complications, and subsequent outcomes following CRT implantation compared to younger patients.
Methods:
We conducted a retrospective cohort study of unselected, consecutive patients implanted with CRT devices between March 2008 and July 2017. We recorded complications, symptomatic and echocardiographic response, hospitalisation for heart failure, and all-cause mortality comparing patients aged <70, 70-79 and ≥ 80 years.
Results:
Five hundred and seventy-four patients (median age 76 years [interquartile range 68-81], 73.3% male) received CRT. At baseline, patients aged ≥80 years had worse symptoms, were more likely to have co-morbidities, and less likely to be receiving comprehensive medical therapy, although left ventricular function was similar. Older patients were less likely to receive CRT-defibrillators compared to CRT-pacemakers. Complications were infrequent and not more common in older patients. Age was not a predictor of symptomatic or echocardiographic response to CRT (67.2%, 71.2% and 62.6% responders in patients aged <70, 70-79 and ≥ 80 years, respectively; P = 0.43), and time to first heart failure hospitalisation was similar across age groups (P = 0.28). Ten-year survival was lower for older patients (49.9%, 23.9% and 6.8% in patients aged <70, 70-79 and ≥ 80 years, respectively; P < 0.001).
Conclusions:
The benefits of CRT on symptoms and left ventricular function were not different in older patients despite a greater burden of co-morbidities and less optimal medical therapy. These findings support the use of CRT in an ageing population.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Heart Failure Drugs: β-Blockers


